Tirzepatide is a dual incretin receptor agonist that activates both GLP-1 and GIP receptors, used for glycemic control and weight management. It's typically administered once weekly via subcutaneous injection, with dosing starting at 2.5 mg and gradually increasing over 4-week intervals to a maintenance range. The peptide is reconstituted with bacteriostatic water for subcutaneous delivery.
- Dual GLP-1 and GIP receptor agonist.
- Administered once weekly via subcutaneous injection.
- Commonly used for type 2 diabetes and weight management.
- Gradual dose escalation minimizes gastrointestinal side effects.
- Supports significant reductions in HbA1c and body weight.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
2 mL
Concentration
5 mg/mL
1 unit = 0.01 mL = 50 mcg (U-100 syringe)
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 2Inject water slowly down the vial wall to avoid foaming.
- 3Gently swirl or roll the vial until the peptide is fully dissolved (do not shake).
- 4Label the reconstituted vial with the date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 5Use the reconstituted solution within 28 days.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-4 | 2.5 mg | 50 units (0.50 mL) |
| Weeks 5-8 | 5 mg | 100 units (1.0 mL) |
| Weeks 9-12 | 7.5 mg | 75 units (0.75 mL) x 2 injections |
| Weeks 13-16 | 10 mg | 100 units (1.0 mL) x 2 injections |
Protocol detail
| Start | 2.5 mg once weekly for 4 weeks (initiation dose). |
|---|---|
| Escalate | Increase by 2.5 mg every 4 weeks as tolerated. |
| Maintenance | 5–15 mg weekly based on response and tolerability. |
| Frequency | Once per week (subcutaneous), same day each week. |
| Timing | Any time of day; with or without food; rotate injection sites. |
Overview at a glance
| Goal | Support glycemic control, weight management, and metabolic health through dual incretin receptor activation. |
|---|---|
| Schedule | Weekly subcutaneous injection on the same day each week for 12–16+ weeks. |
| Dose Range | 2.5–15 mg weekly with 4‑week titration intervals. |
| Reconstitution | 2.0 mL per 10 mg vial (5.0 mg/mL) for manageable injection volumes. |
| Storage | Lyophilized frozen; reconstituted refrigerated for up to 28 days. |
How it works
Tirzepatide functions as a dual agonist, simultaneously targeting GLP-1 and GIP receptors. This dual action stimulates glucose-dependent insulin release, suppresses glucagon production, slows gastric emptying, and promotes satiety through central appetite regulation. The combination of GIP and GLP-1 receptor activation amplifies metabolic benefits, leading to improved glycemic control and significant weight reduction compared to GLP-1 agonists alone. Its prolonged half-life, approximately five days, allows for a convenient once-weekly dosing schedule.
Reported effects
- Significant HbA1c reductions
- Substantial body-weight loss
- Improved lipid profiles
- Reduced blood pressure
Reported side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Injection-site reactions
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure.
After reconstitution
Refrigerate at 2-8 °C (35.6-46.4 °F), protected from light. Do not freeze. Use within 28 days.
Supplies
| Peptide vials (10 mg each) | Approximately 3-10 vials for an 8-16 week protocol. |
|---|---|
| Insulin Syringes (U-100, 1 mL) | Approx. 8-24 syringes for an 8-16 week protocol. |
| Bacteriostatic Water (10 mL bottles) | Approx. 1-2 bottles for an 8-16 week protocol (2.0 mL per vial). |
| Alcohol Swabs | Recommend 1 x 100-count box for an 8-16 week protocol. |
Important notes
- Always use new sterile insulin syringes and dispose of them safely in a sharps container.
- Rotate injection sites to reduce local irritation and prevent lipohypertrophy.
- If a dose requires multiple injections, administer them consecutively at different sites on the same day.
- Inject slowly and allow a few seconds before withdrawing the needle.
- Initial gastrointestinal side effects are common; gradual dose titration helps manage them.
Frequently asked questions
How long does it take to see results with Tirzepatide?
Results can vary, but improvements in glycemic control and weight reduction are typically observed within the first few weeks to months, with more significant changes over several months of consistent use and dose titration.
Can I adjust my own Tirzepatide dose?
Dose adjustments should always be managed by a healthcare professional. The protocol outlines a gradual titration schedule designed to maximize benefits while minimizing side effects, and individual changes may require medical guidance.
What should I do if I miss a dose of Tirzepatide?
If you miss a dose, administer it as soon as you remember, provided your next scheduled dose is at least 3-4 days away. If it's closer to your next dose, skip the missed dose and resume your regular weekly schedule. Do not double your dose.
Is Tirzepatide suitable for everyone looking to lose weight?
Tirzepatide is specifically indicated for individuals with type 2 diabetes and/or obesity. Its suitability depends on individual health factors, medical history, and potential contraindications, and it should only be used under medical supervision.
Educational reference only. These figures summarise how Tirzepatide is commonly described in research literature and supplier documentation, including the Tirzepatide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Tirzepatide (15 mg Vial)
Dual agonist for glucose control and weight management.
Tirzepatide (20 mg Vial)
Dual agonist for glucose control and weight management.
Tirzepatide (30 mg Vial)
Dual GLP-1/GIP agonist for glycemic control and weight management.
Tirzepatide (40 mg Vial)
Dual GLP-1/GIP agonist for glycemic control and weight management.